The disclosure relates to a use of a selective AT2 receptor antagonist compound of formula (I) in the manufacture of a medicament for the effective treatment of impaired nerve signal conduction, wherein the variables are as defined in the specification. Also disclosed are compositions including selective AT2 receptor antagonists as active agents that are suitable for use in relation to improving nerve signal conduction or reversing impaired nerve signal conduction.
